CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Aug 8, 2025
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -
Read more at globenewswire.com
